AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03422354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Aneasthesia
Description: General Aneasthesia
Study NCT03558360 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Impedance measurement
Description: Measurement of dry lean body mass berfore bariatric surgery by impedance measurement.
Study NCT01383772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pan retinal Photocoagulation
Description: All patients with bilateral proliferative diabetic retinopathy requiring bilateral pan retinal photocoagulation will undergo baseline visual field tests prior to commencing laser treatment. These fields will be repeated at 6 months following completion of laser treatment.
Study NCT04354844 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: questionnaire
Study NCT03588728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation targeting the right inferior frontal gyrus
Study NCT03588728 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation targeting the right inferior frontal gyrus
Study NCT03588728 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Remediation (CR)
Description: Cognitive exercises on a computer designed to increase attention, memory, and processing speed.
Study NCT03588728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Description: Cognitive exercises on a computer designed to increase attention, memory, and processing speed.
Study NCT01222273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: cholecalciferol (Vitamin D3)
Description: 4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
Study NCT01130584 — intervention group
Intervention type: OTHER
Intervention: Pyruvate kinase isoform M2
Study NCT01932554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission. All patients will receive standard supportive care measures.
Study NCT01932554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
Study NCT01932554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous hydration
Description: intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements
Study NCT01932554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous hydration
Description: intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements
Study NCT01932554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Scheduled ibuprofen,\~10 mg/kg every 6-8 hours
Study NCT01932554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Scheduled ibuprofen,\~10 mg/kg every 6-8 hours
Study NCT01932554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral narcotic
Description: Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.
Study NCT01932554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parenteral narcotic
Description: Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.
Study NCT01932554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Description: Patients will perform incentive spirometry every 2 hours while awake
Study NCT01932554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Incentive spirometry
Description: Patients will perform incentive spirometry every 2 hours while awake
Study NCT01932554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Description: Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.
Study NCT01932554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supplemental oxygen
Description: Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.
Study NCT03650257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp96
Description: 25 mcg IH
Study NCT03650257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 23 days , 28 days for a a cycle, a total of 6 cycles ).
Study NCT03650257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 23 days , 28 days for a a cycle, a total of 6 cycles ).
Study NCT03650257 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Stupp regimen of radiotherapy
Study NCT03650257 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Stupp regimen of radiotherapy
Study NCT01551160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A communication and team-working intervention
Description: Medical Emergency Team (MET) briefings and formalised handover between MET staff and patient care teams
Study NCT02652273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept 125mg/ml
Study NCT02832154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Complete online PA program
Study NCT02832154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02832154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00913120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT00913120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT00913120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: injection
Study NCT02699983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Use SparkPeople web-based program
Study NCT02699983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Use Fitbit monitor and SparkPeople web-based program
Study NCT02699983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Monitoring Device
Description: Wear Fitbit activity monitoring device
Study NCT02699983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity Monitoring Device
Description: Wear Fitbit activity monitoring device
Study NCT04457167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted
Description: robot-assisted surgery
Study NCT04457167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Not robot-assisted surgery
Description: Not robot-assisted surgery
Study NCT00887432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO
Study NCT00887432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00887432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Study NCT00887432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO
Study NCT00887432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00887432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03658668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: tDCS is a therapeutic treatment that utilizes low amplitude direct currents (\<4 mA) to induce changes in cortical excitability.
Study NCT03658668 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: During a sham session, the device is programmed to ramp up to the desired intensity (target 2.5 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
Study NCT03658668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Description: 20 minutes of cycling on an ergonomic cross-trainer
Study NCT03658668 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical Activity (PA)
Description: 20 minutes of cycling on an ergonomic cross-trainer
Study NCT03800459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family empowerment program
Description: The empowerment program-nursing interventions were given in 6 sessions in the experimental group Session 1: Individualized training: General information about CF, respiratory system involvement and treatment process, airway cleaning in CF, drug applications (45-50 min) Session 2:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min).Session 3:Phone calls:Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min) Session 4:Individualized training:protection from infections, nutrition and psychosocial support (45 min) Session 5:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min) Session 6:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min)
Study NCT00108147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circuit Training
Study NCT00108147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation
Study NCT00108147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility and toning
Study NCT00756470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.
Study NCT00756470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.
Study NCT00756470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 500 mg/m\^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.
Study NCT00756470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m\^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.
Study NCT00756470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
Study NCT02418273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: These subjects will receive two doses of denosumab.
Study NCT01008215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm
Description: Warfarin Dosing algorithm (paper and electronic version)
Study NCT01718782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask Ambu AuraOnce
Description: airway management and mechanical ventilation with laryngeal mask
Study NCT01718782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask LMA Supreme
Description: airway management and mechanical ventilation with laryngeal mask
Study NCT04317703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin tartrate sesquihydrate and metformin
Description: Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
Study NCT04317703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release
Description: Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base).
Study NCT04316208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP variations
Description: Patients will be ventilated with a PEEP of 5 cmH2O during induction of anesthesia. After craniotomy, the PEEP will be reduced to 0 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Next, PEEP will be increased to 5 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Finally, PEEP will be increased to 10 cmH2O for 5 minutes and data will be collected at the end of 5 minutes.
Study NCT01684267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Gait Rehabilitation (RGR) Trainer
Study NCT02871310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AS-118
Description: 1 tablet in the morning
Study NCT02871310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet in the morning
Study NCT00302419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intracoronary infusion,
Description: streptokinase, 250,000 units
Study NCT00302419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary percutaneous coronary angioplasty
Study NCT00302419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary percutaneous coronary angioplasty
Study NCT03130010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam or saline
Description: One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.
Study NCT03130010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nefopam or saline
Description: One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.
Study NCT01284660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: DHA ingested orally by heavy smokers
Study NCT01284660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral ingestion of 5 placebo tablets
Description: Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
Study NCT02123433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal conjugate 13 valent vaccine
Description: Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).~Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.~Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm.
Study NCT00998426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose monitoring before and after HepaGam B administration
Description: Glucose monitoring before and after HepaGam B administration. Prior to receiving the dose of HepaGam B HBIG, blood glucose will be monitored in 3 manners. These will include two finger stick tests, one with a glucose-specific monitoring device and one with a glucose non-specific monitoring device; a venous blood glucose level; and a urine glucose test. Patients will receive the HBIG infusion and then immediately after the dose will have the same blood glucose tests repeated (finger sticks, venous glucose and urine glucose). Then at 60 minutes and 120 minutes after the dose is given, patients will again have finger stick tests with the glucose specific and glucose non-specific monitoring devices.
Study NCT00998426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaGam B (Hepatitis B Immune Globulin (HBIG))
Description: Subjects will be given 20,000 IU HepaGam B after the initial blood glucose monitoring, and prior to the post-infusion blood glucose monitoring.
Study NCT04101604 — intervention group
Intervention type: OTHER
Intervention: Collection of blood samples
Description: Collection of blood samples for DNA extraction and genetic characterization, and for identification of peripheral blood biomarkers using single-cell transcriptomics and mass cytometry.
Study NCT03118674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harvoni
Description: One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
Study NCT02388646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Only
Description: This group will be given a set of 2 exercises to complete at home. The exercises are designed to strengthen the quadriceps muscle group.
Study NCT02388646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brace Only
Description: This group will be fitted with a Reaction Web brace and asked to wear it when going about activities of daily living.
Study NCT02388646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bracing + Exercises
Description: This group will be asked to both wear the Reaction Web brace during activities of daily living and complete a set of 2 exercises designed to strengthen the quadriceps muscle group.
Study NCT01661478 — intervention group
Intervention type: OTHER
Intervention: Training on motivational interviewing
Study NCT02682641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBRUTINIB
Description: Ibrutinib 560 mg daily po for 28 days (cycle one). Continuous cycles until disease progression or unacceptable toxicity.
Study NCT02682641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1, 4 doses). Rituximab 375 mg/m2 iv, day one of every other cycle for 4 doses (cycle 3, 5, 7 and 9).
Study NCT03285178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1701
Description: Oral Tablet
Study NCT03285178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study NCT01116986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt
Description: If randomized to this condition:~After the target quit day:~Patch:~IF > 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.~Gum:~IF > 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks.
Study NCT00502827 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cell Phone Intervention
Description: Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.
Study NCT00502827 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Recommended Standard of Care
Description: Advice from your physician to stop smoking and written materials designed to help you quit smoking.
Study NCT01340820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AERAS-422
Description: rBCG
Study NCT01340820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG Tice
Description: 1-8 x 10\^5 CFU
Study NCT04452396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of continuous glucose monitoring
Description: Patients will wear a CGM device whilst undergoing diagnostic testing for reactive/spontaneous hypoglycaemia and then optimisation of anti-hypoglycaemic medication.
Study NCT01642173 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography (C7 XR Dragonfly )
Description: Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.